MEDIBANK PRIVATE LIMITED (MPL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MPL - MEDIBANK PRIVATE LIMITED

FNArena Sector : Insurance
Year End: June
GICS Industry Group : Insurance
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Medibank Private is the largest Australian private health insurance provider. Previously an Australian Government business enterprise, established by the Whitlam government in 1975, it was privatised in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.88

05 Dec
2022

-0.050

OPEN

$2.91

-1.71%

HIGH

$2.92

9,506,424

LOW

$2.88

TARGET
$3.239 12.5% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
IAG . ISU . NHF . QBE . SDF . SUN . TWR . CVW . GDG . PSI . FCL . NOL .
FNARENA'S MARKET CONSENSUS FORECASTS
MPL: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx 14.3 16.2 xxx
DPS (cps) xxx 13.4 14.3 xxx
EPS Growth xxx - 10.7% 13.1% xxx
DPS Growth xxx 5.5% 6.6% xxx
PE Ratio xxx N/A 17.8 xxx
Dividend Yield xxx N/A 5.0% xxx
Div Pay Ratio(%) xxx 93.7% 88.3% xxx

Dividend yield today if purchased 3 years ago: 4.17%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 4.57

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 7.3c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx14.3
DPS All xxxxxxxxxxxxxxx13.4
Sales/Revenue xxxxxxxxxxxxxxx7,197.7 M
Book Value Per Share xxxxxxxxxxxxxxx70.6
Net Operating Cash Flow xxxxxxxxxxxxxxx962.7 M
Net Profit Margin xxxxxxxxxxxxxxx5.47 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx20.45 %
Return on Invested Capital xxxxxxxxxxxxxxx19.88 %
Return on Assets xxxxxxxxxxxxxxx9.29 %
Return on Equity xxxxxxxxxxxxxxx20.45 %
Return on Total Capital xxxxxxxxxxxxxxx27.83 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx597.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

27/10/2022

3

Downgrade to Neutral from Buy

$3.00

4.17%

The full impact of Medibank Private's data breach remains uncertain, and the company has withdrawn its full year policy holder guidance amid uncertainty. Citi expects the reaction of consumers will be key to Medibank Private's outlook, but notes this is hard to predict. 

Marking to market, Citi has pulled back its policyholder growth assumptions -6%, -10% and -12% through to FY25. The broker anticipates some policyholder contraction in the coming two years, before recovery in FY25.

The rating is downgraded to Neutral from Buy and the target price decreases to $3.00 from $4.00.

FORECAST
Citi forecasts a full year FY23 dividend of 14.60 cents and EPS of 17.90 cents.
Citi forecasts a full year FY24 dividend of 14.60 cents and EPS of 16.90 cents.

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

MPL STOCK CHART

FNArena News on MPL

1
In Brief: Inflation, Cyber Security, Dividends

Nov 18 2022 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Nov 04, 2022

Nov 04 2022 - Daily Market Reports
3
Weekly Ratings, Targets, Forecast Changes – 28-10-22

Oct 31 2022 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Oct 07, 2022

Oct 07 2022 - Daily Market Reports
5
Rudi’s View: Woodside, REA, QBE, Appen & Megaport

Sep 08 2022 - Rudi's View

Latest Insurance News

1
Climate Costs Burden Heaviest For Aussie Insurers

Jun 01 2022 - Australia
2
In Brief: Risks From Russia, House Prices And Insurance Brokers

Feb 04 2022 - Australia
3
IAG Fails The Weather Test, But All Is Not Lost

Nov 03 2021 - Australia
4
Growth Returns For Suncorp

Aug 10 2021 - Australia
5
Treasure Chest: IAG Re-Rating?

Jun 28 2021 - Treasure Chest
6
Insurers Grapple With Costs And Competition

Jun 16 2021 - Australia
7
Nib Holdings May Need To Tread Carefully

Apr 27 2021 - Australia
8
Insurers Tackle More Risk As NSW Floods

Mar 23 2021 - Australia
9
Suncorp Homes In On Improved Returns

Feb 10 2021 - Australia
10
Reinsurance Key To Insurer Pandemic Claims

Sep 16 2020 - Australia